Resources

PPTA prepares policy documents (such as issue briefs, statements, backgrounds, and white papers) on a variety of policy topics that are relevant to protecting patient access and are important to the association and its members.

Plasma protein therapies replace missing or deficient proteins that allow individuals to lead healthy and more productive lives. The patients that rely on these therapies generally require regular infusions or injections throughout their lives. The diseases and conditions treated by plasma protein therapies are considered rare diseases because they affect a relatively small percent of the population. Most are genetic, chronic conditions.

In collaboration with industry regulators and stakeholders, PPTA has developed a system that we believe is the best way to present the distribution of core plasma protein therapies in North America.

Recently, several media outlets have reported on access issues regarding immunoglobulin (Ig) therapies. The Plasma Protein Therapeutics Association (PPTA) represents the private collectors of plasma and the manufacturers of plasma-derived therapies that treat rare, serious, genetic, and — in many cases — life-threatening diseases caused by missing or nonfunctioning proteins typically found in plasma.